

Bod Science provides significant updates on Phase IIB clinical trial of Schedule 3 CBD product for Australian market

- Bod's Phase IIB clinical trial is the only advanced Schedule 3 CBD product candidate for the Australian market
- 'Last patient, last visit' milestone imminently anticipated in early July 2023
- Agreement with Arrotex Pharmaceuticals varied to accommodate receipt of top line clinical trial results
- Topline clinical trial results are expected to be available in August 2023
- Dossier submission expected in the final quarter of the calendar year

Sydney, Australia – 3 July 2023: Cannabis focused drug development and product innovation company Bod Science Limited ("Bod" or "the Company") (ASX: BOD) is pleased to provide the following update on an upcoming milestone in their phase IIB clinical trial for a new Schedule 3 CBD product for the Australian market being undertaken by Australia's leading sleep research organisation, the Woolcock Institute of Medical Research.

The trial assesses the efficacy of a uniquely developed Schedule 3 (Pharmacist Only) CBD formulation on symptoms associated with insomnia in 198 participants over 8 weeks. Schedule 3 products can be sold to Australian consumers over-the-counter without a prescription. Bod's trial is a double blind, randomised and placebo-controlled investigation of the effect of administering 50mg and 100mg oral doses of a proprietary CBD product per day versus a placebo, (refer ASX announcement: 22 September 2021). The Phase IIB clinical trial is the final step in R&D for the new product. Bod's unique CBD formulation is presented in a soft gel format and utilises a patent protected encapsulation technology that improves the bioavailability of the CBD extract. The clinical trial is the only advanced Schedule 3 CBD product candidate for the Australian market.

With the upcoming milestone of 'last patient last visit' anticipated in early July, Bod is looking forward to the outcomes of the Schedule 3 trial. In conjunction with Arrotex Pharmaceuticals (who will have the exclusive distribution rights for Bod's Schedule 3 product), research partners and statisticians, Bod has decided to report results of the trial when all key data points are available and the database has been locked. Trial results are expected in August 2023.

Once the results are reported, Bod intends to submit the dossier to the TGA for their review of what is anticipated to be the first Schedule 3 CBD product to be made available in Australia. The submission is expected in the final quarter of the calendar year.

In line with the anticipated reporting dates, a revised Product Schedule has been executed to vary the In-Licensing and Supply Agreement between Arrotex Pharmaceuticals and Bod Australia, by changing the sunset clause for the successful completion of the study from 30 June 2023, to 31 October 2023.

Management commentary:

CEO Ms Jo Patterson said: "Bod's Phase IIB clinical trial is imminently reaching milestone status with 'last patient, last visit' expected in early July, and as the only advanced Schedule 3 product candidate for the Australian market, we're delighted with the progress.

"With a potential market valued at \$250m, advancement as promptly as possible to product registration of a new, low dose CBD product for the Australian market will be our focus following the results from all data endpoints expected in August 2023."

This announcement has been approved by the Board of Bod Science Limited.

-ENDS-

About Bod Science:

Bod Science (ASX:BOD) is a cannabis focused drug development and product innovation company.

Bod is focused on progressing research and development with a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for patients and consumers.

The company has a number of existing partnerships with large corporate companies and collaborations with leading research organisations to advance the use of Cannabis related medicines with therapeutic indications.

For more information please contact:

Jo Patterson
Chief Executive Officer
Info@bodaustralia.com
+61 2 9199 5018

Amalie Schreurs
White Noise Communications
amalie@whitenoisecomms.com
+61 431 636 033